Targeted Oncology

Oncology news and insights from leading researchers and cancer centers.

[Targeted Oncology @TargetedOnc]

Can a personalized mRNA vaccine help prevent melanoma recurrence? 🧬 New findings on intismeran autogene plus pembrolizumab highlight the potential of individualized neoantigen therapy in high-risk #melanoma.

Read more: https://t.co/B1js9uJtHl

#ESMO26 #Oncology #SkinCancer

[Targeted Oncology @TargetedOnc]

🫁 Without head-to-head data, how can clinicians determine which patients with advanced #NSCLC may be candidates for dual #immunotherapy?

@MattGubensMD @UCSFCancer discusses key clinical and molecular characteristics that can help inform this choice.

[Targeted Oncology @TargetedOnc]

🔎 FDA News: Following an end-of-phase 2 meeting with the #FDA, a phase 3 trial of oral RGT-61159 is planned in #AdenoidCysticCarcinoma in the first quarter of 2027.

Read more: https://t.co/B9TOUf4Joi

#CancerResearch #Oncology #ClinicalResearch #CancerTreatment #RareDiseases

[Targeted Oncology @TargetedOnc]

💬 During a live event, Dr Robert Orlowski (@UTMDAnderson) and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple #myeloma.

Read more: https://t.co/IAQOrSfpzO

@Myeloma_Doc

[Targeted Oncology @TargetedOnc]

Matthew Gubens, MD, MS (@UCSFCancer) explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic #NSCLC.

🎥 WATCH: https://t.co/f0zyy23inc

#LungCancer #Immunotherapy #Oncology
#CancerTreatment | @MattGubensMD

[Targeted Oncology @TargetedOnc]

🔎 FDA News: The #FDA has granted fast track designation to SBE303, an investigational Nectin-4–targeting ADC, for advanced #UrothelialCancer following enfortumab vedotin.

Read more: https://t.co/O8OpsaINT9

#BladderCancer #GUOncology #CancerTreatment

[Targeted Oncology @TargetedOnc]

Real-world evidence has shed new light on prostate cancer treatment strategies. Alicia Morgans, MD, MPH, @DanaFarber, discusses the real-world ARAAT trial and its key findings. https://t.co/sEXVxNQcVU

[Targeted Oncology @TargetedOnc]

🔬 The ADC sofetabart mipitecan showed efficacy and safety in #OvarianCancer, leading to selection of a phase 3 dose for the FRAmework-01 trial.

Read more: https://t.co/OdnFXgkF5J

#GynOnc #Oncology #CancerTreatment #CancerResearch

[Targeted Oncology @TargetedOnc]

🔎 FDA News: The #FDA has granted orphan drug designation to onvansertib for R/R #CMML, boosting development of the PLK1 inhibitor after early signals of activity.

Read more: https://t.co/jDz5vWfGWw

#Leukemia #Hematology #Oncology #BloodCancer #CancerTreatment

[Targeted Oncology @TargetedOnc]

🚨 Our coverage of #ESMO26 starts tomorrow! Visit https://t.co/zzqRTO4Vh7 for exclusive interviews and comprehensive coverage of the meeting's top news. 📰

[Targeted Oncology @TargetedOnc]

🔬 Discharge doesn’t necessarily mean the end of toxicity management after lifileucel (Amtagvi) TIL therapy for advanced #melanoma.

New findings in @JCO_ASCO highlight postdischarge AEs and the importance of continued monitoring. Read more: https://t.co/80gvIs50V9

[Targeted Oncology @TargetedOnc]

Something new is coming into focus. 👀

A fresh look.
A new chapter.

The same commitment to connecting science with everyday practice.

Stay tuned. The reveal is coming soon. 🔜

#ComingSoon #Oncology

[Targeted Oncology @TargetedOnc]

🩺 Practice Update: The @NCCN guidelines have incorporated cosibelimab (Unloxcyt) for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.

Read more: https://t.co/GQDOe2ps7c

#CSCC #SkinCancer #Oncology #CancerCare

[Targeted Oncology @TargetedOnc]

Morana Vojnic, MD, MBA (@RutgersCancer) discussed how FET-PET imaging, advanced molecular testing, and personalized treatment approaches are shaping the future of brain tumor care.

💬 Full interview: https://t.co/IA8B6a2npU

#NeuroOncology #PrecisionMedicine | @Moranaaa

[Targeted Oncology @TargetedOnc]

🔬 A new analysis reveals major gaps in US #TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities.

Read more: https://t.co/39fmvsdFFs

#RuralHealth #CancerCare #ClinicalTrials #BreastCancer

[Targeted Oncology @TargetedOnc]

Alicia Morgans, MD, MPH (@DanaFarber) discusses findings from ARAAT, a real-world analysis comparing darolutamide vs abiraterone when each is added to an ADT and docetaxel backbone in #mHSPC.

🎥 WATCH: https://t.co/gCGX1YC8lt

#Oncology #ProstateCancer #RWD | @CaPsurvivorship

[Targeted Oncology @TargetedOnc]

🔬 The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with #PolycythemiaVera receiving standard-of-care therapy.

Read more: https://t.co/lM7wxDnzh7

#Hematology #ClinicalResearch

[Targeted Oncology @TargetedOnc]

🔎 FDA News: MC001, an investigational chemoimmunotherapy ADC, has received #FDA fast track designation for #PancreaticCancer.

Read more: https://t.co/rA89TEnnxK

#Oncology #CancerTreatment #GIOncology

[Targeted Oncology @TargetedOnc]

🔬 Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell #RCC, alone and in key first-line combinations.

Read more: https://t.co/ujgrk4wOzx

#ccRCC #KidneyCancer #GUOncology #Oncology

[Targeted Oncology @TargetedOnc]

📊 According to a new analysis, rural #BreastCancer deaths are rising faster than urban rates, driven by low income, later diagnosis, and treatment gaps.

Read more: https://t.co/IReLjom8LR

#CancerCare #HealthDisparities #PublicHealth #Epidemiology